These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

355 related articles for article (PubMed ID: 5029971)

  • 1. The regulatory role of the United States Food and Drug Administration.
    Ortiz EM
    J Reprod Med; 1972 Apr; 8(4):205-6. PubMed ID: 5029971
    [No Abstract]   [Full Text] [Related]  

  • 2. Professional drug labeling.
    Terry M
    J Am Vet Med Assoc; 1993 May; 202(10):1711-2;discussion 1713-7. PubMed ID: 8514591
    [No Abstract]   [Full Text] [Related]  

  • 3. Package inserts, adverse drug reactions, and the physician's liability.
    Morrell MX
    Ration Drug Ther; 1975 Aug; 9(8):1-6. PubMed ID: 1144773
    [No Abstract]   [Full Text] [Related]  

  • 4. Relative efficacy.
    J Okla State Med Assoc; 1973 Mar; 66(3):115-20. PubMed ID: 4689645
    [No Abstract]   [Full Text] [Related]  

  • 5. Relative efficacy. When the government decides what drug should be prescribed, is the patient better served?
    J Med Assoc State Ala; 1972 Sep; 42(3):200-12. PubMed ID: 5070864
    [No Abstract]   [Full Text] [Related]  

  • 6. FDA regulatory compliance reconsidered.
    Tobias C
    Cornell Law Rev; 2008 Jul; 93(5):1003-38. PubMed ID: 18618969
    [No Abstract]   [Full Text] [Related]  

  • 7. Black box warnings in prescription drug labeling: results of a survey of 206 drugs.
    Beach JE; Faich GA; Bormel FG; Sasinowski FJ
    Food Drug Law J; 1998; 53(3):403-11. PubMed ID: 10346718
    [No Abstract]   [Full Text] [Related]  

  • 8. Over-the-counter human drugs; labeling requirements; final rule; technical amendment. Food and Drug Administration, HHS. Final rule; technical amendment.
    Fed Regist; 2000 Jan; 65(1):7-9. PubMed ID: 11010625
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Drug labeling for teratogenicity: requirements of the U.S. Food and Drug Administration.
    Kelsey FO
    Prog Clin Biol Res; 1985; 163C():155-9. PubMed ID: 3991617
    [No Abstract]   [Full Text] [Related]  

  • 10. Constraints on innovation in drug development and use.
    Lasagna L
    Psychopharmacol Bull; 1972 Apr; 8(2):43-50. PubMed ID: 4550369
    [No Abstract]   [Full Text] [Related]  

  • 11. Scientific basis for nonapproved use of drugs in veterinary practice.
    Brumbaugh GW
    J Am Vet Med Assoc; 1993 May; 202(10):1693-6;discussion 1713-7. PubMed ID: 8514586
    [No Abstract]   [Full Text] [Related]  

  • 12. FDA perspectives on supplement use by patients on antithrombotic therapy: dietary supplement regulatory overview.
    Woo JJ
    Thromb Res; 2005; 117(1-2):193-6; discussion 201-7. PubMed ID: 16253311
    [No Abstract]   [Full Text] [Related]  

  • 13. Sounding board. Creative tension: FDA and medicine.
    Kennedy D
    N Engl J Med; 1978 Apr; 298(15):846-50. PubMed ID: 345121
    [No Abstract]   [Full Text] [Related]  

  • 14. The US Food and Drug Administration and probiotics: regulatory categorization.
    Degnan FH
    Clin Infect Dis; 2008 Feb; 46 Suppl 2():S133-6; discussion S144-51. PubMed ID: 18181719
    [TBL] [Abstract][Full Text] [Related]  

  • 15. FDA's regulation of prescription drug labeling: a role for implied preemption.
    Kendrick LC
    Food Drug Law J; 2007; 62(1):227-47. PubMed ID: 17444031
    [No Abstract]   [Full Text] [Related]  

  • 16. Unlabeled drug samples and the learned intermediary: the case for drug company liability without preemption.
    Poser S
    Food Drug Law J; 2007; 62(4):653-94. PubMed ID: 18557225
    [No Abstract]   [Full Text] [Related]  

  • 17. Content and format for labeling for human prescription drugs; amendment of effective date for certain biological products--Food and Drug Administration. Final rule.
    Fed Regist; 1981 Jan; 46(15 pt 1):7271-3. PubMed ID: 10249526
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The history of patient package inserts in the United States.
    Moore SR; Morris LA; Groft SC
    Can Pharm J; 1981 May; 114(5):173-5. PubMed ID: 10251273
    [No Abstract]   [Full Text] [Related]  

  • 19. FDA in hot water again over cost of proposed drug labeling rule.
    Demkovich LE
    Natl J (Wash); 1979 Sep; 11(38):1568-70. PubMed ID: 10243426
    [No Abstract]   [Full Text] [Related]  

  • 20. Adherence to approved drug use as a predictor of length of hospital stay.
    Gibson JT; Idsvoog P
    Am J Hosp Pharm; 1975 Mar; 32(3):280-2. PubMed ID: 1136975
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.